参麦注射液治疗慢性阻塞性肺疾病稳定期并发肺部感染的临床效果

Analysis of clinical effect of Shenmai injection on complicated pulmonary infection in patients with chronic obstructive pulmonary disease in stable stage

目的基于呼吸力学探讨参麦注射液对慢性阻塞性肺疾病(COPD)稳定期肺部感染患者的临床效果。方法选取河北省中医院2022年1月-2022年12月收治的COPD稳定期肺部感染患者146例,随机将其分成两组,其中对照组73例患者实施西医常规治疗,研究组73例患者实施另外给予参麦注射液。两组患者治疗7d后具体的疗效、呼吸力学相关情况、肺功能相应的指标以及膈肌功能相关的指标改变情况予以对比,并计算不良反应出现的具体概率情况。结果有效率方面,研究组相较于对照组更高(93.15%vs.82.19%),治疗后第1秒用力肺活量和预计值比值(FEV1%)、最大呼气峰流速(PEF)以及第1秒用力肺活量和用力肺活量比值(FEV1/FVC)水平高于对照组(P<0.05);经治疗后研究组的平台压(Pplat)、气道峰压(PIP)、气道的阻力(Raw)较对照组低(P<0.05);治疗后研究组膈肌运动度(DE)、膈肌增厚率(DTF)以及膈肌收缩速度高于对照组,而膈肌浅快呼吸指数低于对照组(P<0.05);并发症主要为面色发红、头昏、发热等,症状较轻,均可耐受,不良反应出现概率两组患者对比并无统计学差异。结论在常规治疗基础上联合使用参麦注射液在COPD稳定期肺部感染患者治疗中疗效明显,参麦注射液能够提高膈肌收缩及呼吸力学相关功能,改善肺功能状态,有助于提高临床疗效。

OBJECTIVE To explore the clinical effect of Shenmai injection on pulmonary infection in stable chronic obstructive pulmonary(COPD)invalids based on respiratory mechanics.METHODS A total of 146 patients with stable COPD pulmonary infection admitted to Hebei Provincial Hospital of Traditional Chinese Medicine from Jan 2022 to Dec 2022 were recuited and randomly divided into two groups.Among them,73 patients in the control group were treated with conventional western medicine,and 73 patients in the study group were treated with Shenmai injection.The efficacy after seven days of treatment,respiratory mechanics related conditions,pulmonary function indexes,respiratory mechanics and diaphragm function indexes were compared between the two groups,and the risk of adverse reactions was statistically analyzed.RESULTS The effective rate in the observation group was obvious higher than that in the control group(93.15%vs.82.19%),and the levels of PEF,FEV1/FVC and FEV1%after treatment were higher than those in the control group(P<0.05).After treatment,the peak airway pressure(PIP),plateau pressure(Pplat),and airway resistance(Raw)levels in the study group were lower than those in the control group(P<0.05);diaphragmatic excursion(DE),diaphragm thickening fraction(DFF)and diaphragm contraction speed in the study group were obvious higher than those in the control group,while shallow rapid diaphragm breathing index was lower than that in the control group(P<0.05).The adverse complications were redness,dizziness,fever,etc.,which were mild and could be tolerated.There was no obvious difference in the incidence of adverse events between the groups of patients.CONCLUSION On the basis of routine treatment,the use of Shenmai injection has a significant therapeutic effect on stable COPD patients with pulmonary infection.Shenmai injection can improve the patient's respiratory mechanics function and diaphragm contraction function,improving lung function status and clinical efficacy.